$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000100069421000004 Filed on March 01, 2021

Income Statement

Concept	2019 Q4	2018 Q4	2018
Revenue	$8.800M	$6.127M	$34.29M
YoY Change	43.63%	-41.15%	9.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.200M	$9.200M	$34.40M
YoY Change	-10.87%	8.24%	-0.29%
% of Gross Profit
Research & Development	$29.30M	$43.40M	$173.8M
YoY Change	-32.49%	-12.68%	3.18%
% of Gross Profit
Depreciation & Amortization	$1.000M	$2.000M	$7.400M
YoY Change	-50.0%	-4.76%	-2.63%
% of Gross Profit
Operating Expenses	$37.50M	$52.60M	$173.8M
YoY Change	-28.71%	-9.62%	3.18%
Operating Profit			-$173.9M
YoY Change			1.29%
Interest Expense	-$3.100M	-$2.800M	$13.61M
YoY Change	10.71%	-9.68%	-3.27%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$108.0K
YoY Change			61.19%
Pretax Income	-$31.80M	-$49.30M	-$184.7M
YoY Change	-35.5%	-2.95%	0.49%
Income Tax
% Of Pretax Income
Net Earnings	-$31.80M	-$49.33M	-$184.7M
YoY Change	-35.54%	-2.97%	0.53%
Net Earnings / Revenue	-361.36%	-805.19%	-538.81%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.132M	-$2.568M	-$9.984M
COMMON SHARES
Basic Shares Outstanding		382.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2018 Q4	2018
SHORT-TERM ASSETS
Cash & Short-Term Investments	$78.80M	$92.10M	$92.10M
YoY Change	-14.44%	-41.45%	-41.45%
Cash & Equivalents	$78.82M	$70.15M	$70.20M
Short-Term Investments	$0.00	$22.00M	$22.00M
Other Short-Term Assets	$4.376M	$4.321M	$27.20M
YoY Change	1.27%	-7.85%	-40.87%
Inventory
Prepaid Expenses
Receivables	$7.500M
Other Receivables	$0.00
Total Short-Term Assets	$97.25M	$119.3M	$119.3M
YoY Change	-18.47%	-41.33%	-41.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.45M	$28.43M	$28.40M
YoY Change	-59.74%	-21.01%	-21.11%
Goodwill	$51.15M	$51.97M
YoY Change	-1.56%	-2.98%
Intangibles	$5.581M	$6.541M
YoY Change	-14.68%	-16.92%
Long-Term Investments
YoY Change
Other Assets	$7.120M	$810.0K	$1.800M
YoY Change	779.01%	-6.79%	0.0%
Total Long-Term Assets	$75.71M	$88.70M	$88.70M
YoY Change	-14.65%	-10.57%	-10.58%
TOTAL ASSETS
Total Short-Term Assets	$97.25M	$119.3M	$119.3M
Total Long-Term Assets	$75.71M	$88.70M	$88.70M
Total Assets	$173.0M	$208.0M	$208.0M
YoY Change	-16.84%	-31.25%	-31.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.910M	$9.301M	$9.300M
YoY Change	-68.71%	65.7%	66.07%
Accrued Expenses	$14.87M	$19.55M	$24.60M
YoY Change	-23.95%	-33.98%	-29.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$25.80M	$45.54M	$45.50M
YoY Change	-43.36%	-38.19%	-38.26%
LONG-TERM LIABILITIES
Long-Term Debt	$320.6M	$319.2M	$319.2M
YoY Change	0.44%	0.44%	0.44%
Other Long-Term Liabilities	$12.57M	$8.687M	$11.20M
YoY Change	44.68%	-15.55%	-12.5%
Total Long-Term Liabilities	$12.57M	$8.687M	$330.4M
YoY Change	44.68%	-15.55%	-0.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.80M	$45.54M	$45.50M
Total Long-Term Liabilities	$12.57M	$8.687M	$330.4M
Total Liabilities	$359.0M	$375.9M	$375.9M
YoY Change	-4.51%	-7.0%	-7.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.432B	-$1.299B
YoY Change	10.21%	16.58%
Common Stock	$324.0K	$3.849M
YoY Change	-91.58%	18.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.583M	$2.450M
YoY Change	5.43%	0.0%
Treasury Stock Shares	46.94K shares	$455.4K
Shareholders Equity	-$186.0M	-$167.9M	-$167.9M
YoY Change
Total Liabilities & Shareholders Equity	$173.0M	$208.0M	$208.0M
YoY Change	-16.84%	-31.25%	-31.24%

Cashflow Statement

Concept	2019 Q4	2018 Q4	2018
OPERATING ACTIVITIES
Net Income	-$31.80M	-$49.33M	-$184.7M
YoY Change	-35.54%	-2.97%	0.53%
Depreciation, Depletion And Amortization	$1.000M	$2.000M	$7.400M
YoY Change	-50.0%	-4.76%	-2.63%
Cash From Operating Activities	-$23.70M	-$45.20M	-$184.8M
YoY Change	-47.57%	4.15%	27.93%
INVESTING ACTIVITIES
Capital Expenditures	-$300.0K	-$500.0K	-$1.370M
YoY Change	-40.0%	-28.57%	-67.3%
Acquisitions			$0.00
YoY Change
Other Investing Activities	$0.00	$48.90M	$29.97M
YoY Change	-100.0%	179.43%	-25.37%
Cash From Investing Activities	-$200.0K	$48.30M	$28.60M
YoY Change	-100.41%	187.5%	-20.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$100.1M
YoY Change			57.76%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	30.20M	3.900M	$102.8M
YoY Change	674.36%	-77.59%	59.29%
NET CHANGE
Cash From Operating Activities	-23.70M	-45.20M	-$184.8M
Cash From Investing Activities	-200.0K	48.30M	$28.60M
Cash From Financing Activities	30.20M	3.900M	$102.8M
Net Change In Cash	6.300M	7.000M	-$53.47M
YoY Change	-10.0%	-176.09%	22.01%
FREE CASH FLOW
Cash From Operating Activities	-$23.70M	-$45.20M	-$184.8M
Capital Expenditures	-$300.0K	-$500.0K	-$1.370M
Free Cash Flow	-$23.40M	-$44.70M	-$183.5M
YoY Change	-47.65%	4.68%	30.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	nvax	Stock Purchased During Stock Split Value StockPurchasedDuringStockSplitValue	1000	USD
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001000694
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssets
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:FinanceLeaseLiabilityNoncurrent
CY2016Q1	nvax	Debt Issuance Cost Amortization Period DebtIssuanceCostAmortizationPeriod	P7Y
CY2020	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.05
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	000-26770
CY2020	dei	Entity Registrant Name EntityRegistrantName	NOVAVAX, INC
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-2816046
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	21 Firstfield Road,
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg,
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20878
CY2020	dei	City Area Code CityAreaCode	(240)
CY2020	dei	Local Phone Number LocalPhoneNumber	268-2000
CY2020	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01 per share
CY2020	dei	Trading Symbol TradingSymbol	NVAX
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	5078700000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	73858882	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	553398000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78823000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	157649000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	93880000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2947000	USD
CY2020Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	262012000	USD
CY2019Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	7500000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	181264000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7977000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1248203000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	97247000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1460000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	410000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	179954000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11445000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5725000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5581000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	135379000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	51154000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11758000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7120000	USD
CY2020Q4	us-gaap	Assets Assets	1582479000	USD
CY2019Q4	us-gaap	Assets Assets	172957000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	54332000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2910000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	137390000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14867000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	5078000	USD
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	5078000	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	273228000	USD
CY2019Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1678000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	105862000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3782000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1262000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	579672000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25795000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	322035000	USD
CY2019Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	320611000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	40083000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	13480000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12568000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	955270000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	358974000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71350365	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70953739	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32399352	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32352416	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	714000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	324000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2535476000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1260551000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1874199000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1431801000	USD
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	396626	shares
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	46936	shares
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	41806000	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2583000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7024000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12508000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627209000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-186017000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1582479000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	172957000	USD
CY2020	us-gaap	Revenues Revenues	475598000	USD
CY2019	us-gaap	Revenues Revenues	18662000	USD
CY2018	us-gaap	Revenues Revenues	34288000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	747027000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	113842000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	173797000	USD
CY2020	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	0	USD
CY2019	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	9016000	USD
CY2018	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	0	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	145290000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34417000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34409000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	892317000	USD
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	1014000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	139243000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	208206000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-416719000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-120581000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-173918000	USD
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	1512000	USD
CY2018	us-gaap	Investment Income Net InvestmentIncomeNet	2674000	USD
CY2020	us-gaap	Interest Expense InterestExpense	15145000	USD
CY2019	us-gaap	Interest Expense InterestExpense	13612000	USD
CY2018	us-gaap	Interest Expense InterestExpense	13612000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12591000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	108000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-418259000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-132694000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	19532000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-184748000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.27
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.51
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-9.99
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57554000	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24100000	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18488000	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-418259000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-132694000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-184748000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	12000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	19523000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1322000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2586000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1317000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2574000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-398727000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-134011000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-187322000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-101732000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18314000	USD
CY2018	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	2745000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4265000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	100060000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	12000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2586000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-184748000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-167935000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17048000	USD
CY2019	nvax	Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan	992000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4885000	USD
CY2020	nvax	Stock Issued During Period Value Preferred Stock Beneficial Conversion Increase Decrease StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease	0	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	19523000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-418259000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1655000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	97890000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	5000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1322000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-132694000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-186017000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	199822000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	128035000	USD
CY2020	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	5246000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	11416000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	878850000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	9000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627209000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-418259000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-132694000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-184748000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5676000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8159000	USD
CY2020	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	0	USD
CY2019	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	9016000	USD
CY2018	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	0	USD
CY2020	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
CY2019	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
CY2018	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	-4381000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1424000	USD
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1424000	USD
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1424000	USD
CY2020	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-245861000	USD
CY2019	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	USD
CY2018	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	128035000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	17048000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	18314000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	16504000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-4957000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2451000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	422689000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4202000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1212000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	163161000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-11485000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6744000	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	271545000	USD
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-8331000	USD
CY2018	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-15610000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42541000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-136623000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-184825000	USD
CY2020	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	54622000	USD
CY2019	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1857000	USD
CY2018	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1372000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	165516000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2020	nvax	Proceeds From Sale Of Assets ProceedsFromSaleOfAssets	0	USD
CY2019	nvax	Proceeds From Sale Of Assets ProceedsFromSaleOfAssets	18333000	USD
CY2018	nvax	Proceeds From Sale Of Assets ProceedsFromSaleOfAssets	0	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	363202000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	17484000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	120150000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	205562000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	39500000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	150118000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-377778000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	38492000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28596000	USD
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	199822000	USD
CY2019	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	875623000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	97392000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100060000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	44469000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	992000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2745000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	39087000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	96065000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
CY2018	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	984762000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	98384000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	102805000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2115000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-32000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-48000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	566558000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	221000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-53472000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82180000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81959000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135431000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	648738000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82180000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81959000	USD
CY2020	nvax	Proceeds From Issuance Or Sale Of Equity Not Settled ProceedsFromIssuanceOrSaleOfEquityNotSettled	3227000	USD
CY2019	nvax	Proceeds From Issuance Or Sale Of Equity Not Settled ProceedsFromIssuanceOrSaleOfEquityNotSettled	497000	USD
CY2018	nvax	Proceeds From Issuance Or Sale Of Equity Not Settled ProceedsFromIssuanceOrSaleOfEquityNotSettled	0	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9255000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	49000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	519000	USD
CY2020	nvax	Non Cash Related Transactions For Finance Lease Right Of Use Asset NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset	247599000	USD
CY2019	nvax	Non Cash Related Transactions For Finance Lease Right Of Use Asset NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset	0	USD
CY2018	nvax	Non Cash Related Transactions For Finance Lease Right Of Use Asset NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset	0	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	13705000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	12188000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	12188000	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	Organization<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Novavax, Inc. (“Novavax,” and together with its wholly owned subsidiaries, Novavax AB and Novavax CZ (formerly, Praha Vaccines a.s.), the “Company”) is a late-stage biotechnology company that promotes improved global health through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases and address urgent, global health needs. The Company’s vaccine candidates, including both its coronavirus vaccine candidate, NVX-CoV2373, and its lead influenza vaccine candidate, NanoFlu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">TM</span>, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis and may elicit differentiated immune responses, which may be more efficacious than naturally occurring immunity or traditional vaccines.
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	648738000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82180000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div>
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	553398000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78823000	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments expose the Company to concentration of credit risk and consist primarily of cash and cash equivalents and marketable securities. The Company’s investment policy limits investments to certain types of instruments, including asset-backed securities, high-grade corporate debt securities and money market funds, places restrictions on maturities and concentrations in certain industries and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in financial institutions, which may exceed federally insured limits. The Company has not experienced any losses relating to such accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents.</span></div>
CY2019Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	7500000	USD
CY2019Q4	nvax	Assets Sold Under Agreement Purchase Price Held In Escrow AssetsSoldUnderAgreementPurchasePriceHeldInEscrow	1500000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	553398000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78823000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	93880000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2947000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1460000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	410000	USD
CY2020Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	262000000.0	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	273200000	USD
CY2019Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1700000	USD
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1800000000	USD
CY2020	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	segment
CY2020Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6679629000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4992792000	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2975481000	shares
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	7000000.0	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-12500000	USD
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	157640000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	157649000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	0	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2019Q4	us-gaap	Goodwill Goodwill	51154000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	51967000	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	70662000	USD
CY2019	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2020	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	13563000	USD
CY2019	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-813000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	135379000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	51154000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	13208000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7483000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5725000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11591000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6010000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5581000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	455000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10122000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	455000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	455000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	455000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	455000	USD
CY2020	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-7.04
CY2020	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	475598000	USD
CY2019	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	18662000	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-419896000	USD
CY2019	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-142210000	USD
CY2020	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-7.04
CY2019	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-3.22
CY2019	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-3.22
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7794000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3782000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	105862000	USD
CY2020	nvax	Operating And Financing Lease Liability Current OperatingAndFinancingLeaseLiabilityCurrent	109644000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	40083000	USD
CY2020	nvax	Operating And Financing Lease Liability Noncurrent OperatingAndFinancingLeaseLiabilityNoncurrent	50205000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y6M
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.138
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2462000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	66805000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	242009000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3097000	USD
CY2020	us-gaap	Lease Cost LeaseCost	245106000	USD
CY2020	nvax	Operating Lease Payments Related To Financing Activities OperatingLeasePaymentsRelatedToFinancingActivities	3097000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	63634000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	96065000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5590000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	242009000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	118017000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	44692000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3385000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2393000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2369000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2079000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	172935000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13086000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	159849000	USD
CY2020Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	455.70
CY2020Q4	us-gaap	Supplies Supplies	171602000	USD
CY2015Q3	nvax	Revenue From Contract With Customer Commitment RevenueFromContractWithCustomerCommitment	89100000	USD
CY2019Q4	us-gaap	Supplies Supplies	3601000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	9662000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4376000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	197747000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1102311	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.95
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24469000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17793000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13024000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	179954000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11445000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4300000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5100000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7400000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20752000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7504000	USD
CY2020Q4	nvax	Research And Development Accruals ResearchAndDevelopmentAccruals	99994000	USD
CY2019Q4	nvax	Research And Development Accruals ResearchAndDevelopmentAccruals	6175000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	16644000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1188000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	137390000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14867000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.03
CY2020	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	117000000	USD
CY2016Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	111.20
CY2016Q1	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	10000000.0	USD
CY2016Q1	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	10000000.0	USD
CY2020Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	325000000	USD
CY2019Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	325000000	USD
CY2020Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2965000	USD
CY2019Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	4389000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	322035000	USD
CY2019Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	320611000	USD
CY2020	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	12188000	USD
CY2019	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	12188000	USD
CY2018	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	12188000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1424000	USD
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1424000	USD
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1424000	USD
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	13612000	USD
CY2019	us-gaap	Interest Expense Debt InterestExpenseDebt	13612000	USD
CY2018	us-gaap	Interest Expense Debt InterestExpenseDebt	13612000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	97400000	USD
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	187300000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	500000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	837896	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	94.74
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	840812	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	9.37
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	54415	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	40.37
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1044980	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	72.59
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	128035000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17048000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18314000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	312000000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y3M18D
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-418259000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-132694000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-184748000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.03
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.03
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.04
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.07
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.02
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.03
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.05
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.03
CY2020Q4	nvax	Deferred Tax Asset Leasing Liability DeferredTaxAssetLeasingLiability	39548000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.05
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	13520000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	35065000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	37066000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.31
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.22
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.21
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	325655000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	293736000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	8620000	USD
CY2019Q4	nvax	Deferred Tax Assets Original Discount Interest DeferredTaxAssetsOriginalDiscountInterest	4326000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	12019000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2820000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2512000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1253000	USD
CY2019Q4	nvax	Deferred Tax Asset Leasing Liability DeferredTaxAssetLeasingLiability	2164000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	60657000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	973000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	22577000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	13679000	USD
CY2020Q4	nvax	Deferred Tax Assets Original Discount Interest DeferredTaxAssetsOriginalDiscountInterest	3177000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	507318000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	368284000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	504788000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	365772000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2530000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1033000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1198000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1279000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	79000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	200000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2530000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2512000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	139000000.0	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	28300000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	7353000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1413000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8766000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8800000	USD

Files In Submission

Name	View Source	Status
0001000694-21-000004-index-headers.html	Edgar Link	pending
0001000694-21-000004-index.html	Edgar Link	pending
0001000694-21-000004.txt	Edgar Link	pending
0001000694-21-000004-xbrl.zip	Edgar Link	pending
exhibit1017.htm	Edgar Link	pending
exhibit1018.htm	Edgar Link	pending
exhibit1027.htm	Edgar Link	pending
exhibit1027001.jpg	Edgar Link	pending
exhibit1027002.jpg	Edgar Link	pending
exhibit1027003.jpg	Edgar Link	pending
exhibit1027004.jpg	Edgar Link	pending
exhibit1027005.jpg	Edgar Link	pending
exhibit1027006.jpg	Edgar Link	pending
exhibit1027007.jpg	Edgar Link	pending
exhibit1027008.jpg	Edgar Link	pending
exhibit1027009.jpg	Edgar Link	pending
exhibit1027010.jpg	Edgar Link	pending
exhibit1027011.jpg	Edgar Link	pending
exhibit1027012.jpg	Edgar Link	pending
exhibit1027013.jpg	Edgar Link	pending
exhibit1027014.jpg	Edgar Link	pending
exhibit1027015.jpg	Edgar Link	pending
exhibit1027016.jpg	Edgar Link	pending
exhibit1027017.jpg	Edgar Link	pending
exhibit1027018.jpg	Edgar Link	pending
exhibit1027019.jpg	Edgar Link	pending
exhibit1027020.jpg	Edgar Link	pending
exhibit1027021.jpg	Edgar Link	pending
exhibit1027022.jpg	Edgar Link	pending
exhibit1027023.jpg	Edgar Link	pending
exhibit1027024.jpg	Edgar Link	pending
exhibit1027025.jpg	Edgar Link	pending
exhibit1027026.jpg	Edgar Link	pending
exhibit1027027.jpg	Edgar Link	pending
exhibit1027028.jpg	Edgar Link	pending
exhibit1027029.jpg	Edgar Link	pending
exhibit1027030.jpg	Edgar Link	pending
exhibit1027031.jpg	Edgar Link	pending
exhibit1027032.jpg	Edgar Link	pending
exhibit1027033.jpg	Edgar Link	pending
exhibit1027034.jpg	Edgar Link	pending
exhibit1027035.jpg	Edgar Link	pending
exhibit1027036.jpg	Edgar Link	pending
exhibit1027037.jpg	Edgar Link	pending
exhibit1027038.jpg	Edgar Link	pending
exhibit1027039.jpg	Edgar Link	pending
exhibit1027040.jpg	Edgar Link	pending
exhibit1027041.jpg	Edgar Link	pending
exhibit1027042.jpg	Edgar Link	pending
exhibit1027043.jpg	Edgar Link	pending
exhibit1027044.jpg	Edgar Link	pending
exhibit1027045.jpg	Edgar Link	pending
exhibit1027046.jpg	Edgar Link	pending
exhibit1027047.jpg	Edgar Link	pending
exhibit1027048.jpg	Edgar Link	pending
exhibit1027049.jpg	Edgar Link	pending
exhibit1027050.jpg	Edgar Link	pending
exhibit1027051.jpg	Edgar Link	pending
exhibit1027052.jpg	Edgar Link	pending
exhibit1027053.jpg	Edgar Link	pending
exhibit1027054.jpg	Edgar Link	pending
exhibit1027055.jpg	Edgar Link	pending
exhibit1027056.jpg	Edgar Link	pending
exhibit1035.htm	Edgar Link	pending
exhibit1035001.jpg	Edgar Link	pending
exhibit1035002.jpg	Edgar Link	pending
exhibit1035003.jpg	Edgar Link	pending
exhibit1035004.jpg	Edgar Link	pending
exhibit1035005.jpg	Edgar Link	pending
exhibit1035006.jpg	Edgar Link	pending
exhibit1035007.jpg	Edgar Link	pending
exhibit1035008.jpg	Edgar Link	pending
exhibit1035009.jpg	Edgar Link	pending
exhibit1035010.jpg	Edgar Link	pending
exhibit1035011.jpg	Edgar Link	pending
exhibit1035012.jpg	Edgar Link	pending
exhibit1035013.jpg	Edgar Link	pending
exhibit1035014.jpg	Edgar Link	pending
exhibit1035015.jpg	Edgar Link	pending
exhibit1035016.jpg	Edgar Link	pending
exhibit1035017.jpg	Edgar Link	pending
exhibit1035018.jpg	Edgar Link	pending
exhibit1035019.jpg	Edgar Link	pending
exhibit1035020.jpg	Edgar Link	pending
exhibit1035021.jpg	Edgar Link	pending
exhibit1035022.jpg	Edgar Link	pending
exhibit1035023.jpg	Edgar Link	pending
exhibit1035024.jpg	Edgar Link	pending
exhibit1035025.jpg	Edgar Link	pending
exhibit1035026.jpg	Edgar Link	pending
exhibit1035027.jpg	Edgar Link	pending
exhibit1035028.jpg	Edgar Link	pending
exhibit1035029.jpg	Edgar Link	pending
exhibit1035030.jpg	Edgar Link	pending
exhibit1035031.jpg	Edgar Link	pending
exhibit1035032.jpg	Edgar Link	pending
exhibit1035033.jpg	Edgar Link	pending
exhibit1035034.jpg	Edgar Link	pending
exhibit1035035.jpg	Edgar Link	pending
exhibit1035036.jpg	Edgar Link	pending
exhibit1035037.jpg	Edgar Link	pending
exhibit1035038.jpg	Edgar Link	pending
exhibit1035039.jpg	Edgar Link	pending
exhibit1035040.jpg	Edgar Link	pending
exhibit1035041.jpg	Edgar Link	pending
exhibit1035042.jpg	Edgar Link	pending
exhibit1035043.jpg	Edgar Link	pending
exhibit1035044.jpg	Edgar Link	pending
exhibit1035045.jpg	Edgar Link	pending
exhibit1035046.jpg	Edgar Link	pending
exhibit1035047.jpg	Edgar Link	pending
exhibit1035048.jpg	Edgar Link	pending
exhibit1035049.jpg	Edgar Link	pending
exhibit1035050.jpg	Edgar Link	pending
exhibit1035051.jpg	Edgar Link	pending
exhibit1035052.jpg	Edgar Link	pending
exhibit1035053.jpg	Edgar Link	pending
exhibit1035054.jpg	Edgar Link	pending
exhibit1035055.jpg	Edgar Link	pending
exhibit1035056.jpg	Edgar Link	pending
exhibit1035057.jpg	Edgar Link	pending
exhibit1035058.jpg	Edgar Link	pending
exhibit1035059.jpg	Edgar Link	pending
exhibit1035060.jpg	Edgar Link	pending
exhibit1035061.jpg	Edgar Link	pending
exhibit1035062.jpg	Edgar Link	pending
exhibit1035063.jpg	Edgar Link	pending
exhibit1035064.jpg	Edgar Link	pending
exhibit1035065.jpg	Edgar Link	pending
exhibit1035066.jpg	Edgar Link	pending
exhibit1036.htm	Edgar Link	pending
exhibit1036001.jpg	Edgar Link	pending
exhibit1036002.jpg	Edgar Link	pending
exhibit1036003.jpg	Edgar Link	pending
exhibit1036004.jpg	Edgar Link	pending
exhibit1036005.jpg	Edgar Link	pending
exhibit1036006.jpg	Edgar Link	pending
exhibit1036007.jpg	Edgar Link	pending
exhibit1036008.jpg	Edgar Link	pending
exhibit1036009.jpg	Edgar Link	pending
exhibit1036010.jpg	Edgar Link	pending
exhibit1036011.jpg	Edgar Link	pending
exhibit1036012.jpg	Edgar Link	pending
exhibit1036013.jpg	Edgar Link	pending
exhibit1036014.jpg	Edgar Link	pending
exhibit1036015.jpg	Edgar Link	pending
exhibit1036016.jpg	Edgar Link	pending
exhibit1036017.jpg	Edgar Link	pending
exhibit1036018.jpg	Edgar Link	pending
exhibit1036019.jpg	Edgar Link	pending
exhibit1036020.jpg	Edgar Link	pending
exhibit1036021.jpg	Edgar Link	pending
exhibit1036022.jpg	Edgar Link	pending
exhibit1036023.jpg	Edgar Link	pending
exhibit1036024.jpg	Edgar Link	pending
exhibit1036025.jpg	Edgar Link	pending
exhibit1036026.jpg	Edgar Link	pending
exhibit1036027.jpg	Edgar Link	pending
exhibit1036028.jpg	Edgar Link	pending
exhibit1036029.jpg	Edgar Link	pending
exhibit1036030.jpg	Edgar Link	pending
exhibit1036031.jpg	Edgar Link	pending
exhibit1036032.jpg	Edgar Link	pending
exhibit1036033.jpg	Edgar Link	pending
exhibit1036034.jpg	Edgar Link	pending
exhibit1037.htm	Edgar Link	pending
exhibit1037001.jpg	Edgar Link	pending
exhibit1037002.jpg	Edgar Link	pending
exhibit1037003.jpg	Edgar Link	pending
exhibit1037004.jpg	Edgar Link	pending
exhibit1037005.jpg	Edgar Link	pending
exhibit1037006.jpg	Edgar Link	pending
exhibit1037007.jpg	Edgar Link	pending
exhibit1037008.jpg	Edgar Link	pending
exhibit1037009.jpg	Edgar Link	pending
exhibit1037010.jpg	Edgar Link	pending
exhibit1037011.jpg	Edgar Link	pending
exhibit1037012.jpg	Edgar Link	pending
exhibit1037013.jpg	Edgar Link	pending
exhibit1037014.jpg	Edgar Link	pending
exhibit1037015.jpg	Edgar Link	pending
exhibit1037016.jpg	Edgar Link	pending
exhibit1037017.jpg	Edgar Link	pending
exhibit1037018.jpg	Edgar Link	pending
exhibit1037019.jpg	Edgar Link	pending
exhibit1037020.jpg	Edgar Link	pending
exhibit1037021.jpg	Edgar Link	pending
exhibit1037022.jpg	Edgar Link	pending
exhibit1037023.jpg	Edgar Link	pending
exhibit1037024.jpg	Edgar Link	pending
exhibit1037025.jpg	Edgar Link	pending
exhibit1037026.jpg	Edgar Link	pending
exhibit1037027.jpg	Edgar Link	pending
exhibit1037028.jpg	Edgar Link	pending
exhibit1037029.jpg	Edgar Link	pending
exhibit1041.htm	Edgar Link	pending
exhibit1042.htm	Edgar Link	pending
exhibit1042001.jpg	Edgar Link	pending
exhibit1042002.jpg	Edgar Link	pending
exhibit1042003.jpg	Edgar Link	pending
exhibit1042004.jpg	Edgar Link	pending
exhibit1042005.jpg	Edgar Link	pending
exhibit1042006.jpg	Edgar Link	pending
exhibit1042007.jpg	Edgar Link	pending
exhibit1042008.jpg	Edgar Link	pending
exhibit1042009.jpg	Edgar Link	pending
exhibit1042010.jpg	Edgar Link	pending
exhibit1042011.jpg	Edgar Link	pending
exhibit1042012.jpg	Edgar Link	pending
exhibit1042013.jpg	Edgar Link	pending
exhibit1042014.jpg	Edgar Link	pending
exhibit1042015.jpg	Edgar Link	pending
exhibit1042016.jpg	Edgar Link	pending
exhibit1042017.jpg	Edgar Link	pending
exhibit1042018.jpg	Edgar Link	pending
exhibit1042019.jpg	Edgar Link	pending
exhibit1042020.jpg	Edgar Link	pending
exhibit1042021.jpg	Edgar Link	pending
exhibit1042022.jpg	Edgar Link	pending
exhibit1042023.jpg	Edgar Link	pending
exhibit1042024.jpg	Edgar Link	pending
exhibit1042025.jpg	Edgar Link	pending
exhibit1042026.jpg	Edgar Link	pending
exhibit1042027.jpg	Edgar Link	pending
exhibit1042028.jpg	Edgar Link	pending
exhibit1042029.jpg	Edgar Link	pending
exhibit1042030.jpg	Edgar Link	pending
exhibit1042031.jpg	Edgar Link	pending
exhibit1042032.jpg	Edgar Link	pending
exhibit1042033.jpg	Edgar Link	pending
exhibit1042034.jpg	Edgar Link	pending
exhibit1042035.jpg	Edgar Link	pending
exhibit1042036.jpg	Edgar Link	pending
exhibit1043.htm	Edgar Link	pending
exhibit1043001.jpg	Edgar Link	pending
exhibit1043002.jpg	Edgar Link	pending
exhibit1043003.jpg	Edgar Link	pending
exhibit1043004.jpg	Edgar Link	pending
exhibit1043005.jpg	Edgar Link	pending
exhibit1043006.jpg	Edgar Link	pending
exhibit1043007.jpg	Edgar Link	pending
exhibit1043008.jpg	Edgar Link	pending
exhibit1043009.jpg	Edgar Link	pending
exhibit1043010.jpg	Edgar Link	pending
exhibit1043011.jpg	Edgar Link	pending
exhibit1043012.jpg	Edgar Link	pending
exhibit1043013.jpg	Edgar Link	pending
exhibit1043014.jpg	Edgar Link	pending
exhibit1043015.jpg	Edgar Link	pending
exhibit1043016.jpg	Edgar Link	pending
exhibit1043017.jpg	Edgar Link	pending
exhibit1043018.jpg	Edgar Link	pending
exhibit1043019.jpg	Edgar Link	pending
exhibit1043020.jpg	Edgar Link	pending
exhibit1043021.jpg	Edgar Link	pending
exhibit1043022.jpg	Edgar Link	pending
exhibit1043023.jpg	Edgar Link	pending
exhibit1043024.jpg	Edgar Link	pending
exhibit1043025.jpg	Edgar Link	pending
exhibit1043026.jpg	Edgar Link	pending
exhibit1043027.jpg	Edgar Link	pending
exhibit1043028.jpg	Edgar Link	pending
exhibit1043029.jpg	Edgar Link	pending
exhibit1043030.jpg	Edgar Link	pending
exhibit1043031.jpg	Edgar Link	pending
exhibit1043032.jpg	Edgar Link	pending
exhibit1043033.jpg	Edgar Link	pending
exhibit1043034.jpg	Edgar Link	pending
exhibit1043035.jpg	Edgar Link	pending
exhibit1043036.jpg	Edgar Link	pending
exhibit1043037.jpg	Edgar Link	pending
exhibit1043038.jpg	Edgar Link	pending
exhibit1043039.jpg	Edgar Link	pending
exhibit1043040.jpg	Edgar Link	pending
exhibit1043041.jpg	Edgar Link	pending
exhibit1043042.jpg	Edgar Link	pending
exhibit1043043.jpg	Edgar Link	pending
exhibit1043044.jpg	Edgar Link	pending
exhibit1043045.jpg	Edgar Link	pending
exhibit1043046.jpg	Edgar Link	pending
exhibit1044.htm	Edgar Link	pending
exhibit1044001.jpg	Edgar Link	pending
exhibit1044002.jpg	Edgar Link	pending
exhibit1045.htm	Edgar Link	pending
exhibit1045001.jpg	Edgar Link	pending
exhibit1045002.jpg	Edgar Link	pending
exhibit1045003.jpg	Edgar Link	pending
exhibit1045004.jpg	Edgar Link	pending
exhibit1045005.jpg	Edgar Link	pending
exhibit1045006.jpg	Edgar Link	pending
exhibit1045007.jpg	Edgar Link	pending
exhibit1045008.jpg	Edgar Link	pending
exhibit1045009.jpg	Edgar Link	pending
exhibit1045010.jpg	Edgar Link	pending
exhibit1045011.jpg	Edgar Link	pending
exhibit1045012.jpg	Edgar Link	pending
exhibit1045013.jpg	Edgar Link	pending
exhibit1045014.jpg	Edgar Link	pending
exhibit1045015.jpg	Edgar Link	pending
exhibit1045016.jpg	Edgar Link	pending
exhibit1045017.jpg	Edgar Link	pending
exhibit1045018.jpg	Edgar Link	pending
exhibit1045019.jpg	Edgar Link	pending
exhibit1045020.jpg	Edgar Link	pending
exhibit1045021.jpg	Edgar Link	pending
exhibit1045022.jpg	Edgar Link	pending
exhibit1045023.jpg	Edgar Link	pending
exhibit1045024.jpg	Edgar Link	pending
exhibit1048.htm	Edgar Link	pending
exhibit1049.htm	Edgar Link	pending
exhibit1056.htm	Edgar Link	pending
exhibit21.htm	Edgar Link	pending
exhibit231.htm	Edgar Link	pending
exhibit311.htm	Edgar Link	pending
exhibit312.htm	Edgar Link	pending
exhibit321.htm	Edgar Link	pending
exhibit322.htm	Edgar Link	pending
exhibit44.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_11a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvax-20201231.htm	Edgar Link	pending
nvax-20201231.xsd	Edgar Link	pending
nvax-20201231_cal.xml	Edgar Link	unprocessable
nvax-20201231_def.xml	Edgar Link	unprocessable
nvax-20201231_g1.jpg	Edgar Link	pending
nvax-20201231_g2.jpg	Edgar Link	pending
nvax-20201231_g3.jpg	Edgar Link	pending
nvax-20201231_g4.jpg	Edgar Link	pending
nvax-20201231_g5.jpg	Edgar Link	pending
nvax-20201231_g6.jpg	Edgar Link	pending
nvax-20201231_g7.jpg	Edgar Link	pending
nvax-20201231_htm.xml	Edgar Link	completed
nvax-20201231_lab.xml	Edgar Link	unprocessable
nvax-20201231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2019 Q4 Form 10-K Financial Statement

#000100069421000004 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2019 Q4 Form 10-K Financial Statement

#000100069421000004 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax